Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes... [including commentary by Raymond Plodkowski].
BACKGROUND: It is estimated that 29.1 million people or 9.3% of the US population have diabetes, which contributes to considerable medical and financial burden. Type 2 diabetes mellitus is characterized by insulin resistance and insulin secretion impairment leading to hyperglycemia. The presence of...
| Publicado en: | American Health & Drug Benefits Vol. 10; no. 4; pp. 178 - 189 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | commentary research tables/charts Journal Article |
| Publicado: |
Amplity Health
Jun2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=123937891&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 123937891 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 19422962 6MTU jtl: American Health & Drug Benefits issn: 19422962 maglogo: N pubinfo: dt: Jun2017 vid: 10 iid: 4 pid: 82137 pub: Amplity Health place: East Windsor, New Jersey artinfo: ui: 123937891 123937891 123937891 123937891 ppf: 178 ppct: 11 formats: fmt: @attributes: type: P tig: atl: Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes... [including commentary by Raymond Plodkowski]. aug: au: Lingjet Tran, Kelvin Young In Park Pandya, Shalin Muliyil, Navin John Jensen, Brandon David Huynh, Kovin Quang T. Nguyen affil: Resident, Department of Internal Medicine, Valley Hospital Medical Center, Las Vegas, NV sug: subj: Glucagon-Like Peptide-1 Receptor Agonists Administration and Dosage Diabetes Mellitus, Type 2 Drug Therapy Human Medical Practice, Evidence-Based Decision Making, Clinical Comparative Studies Metformin Administration and Dosage Dipeptidyl Peptidase 4 Inhibitors Administration and Dosage Sulfonylurea Compounds Administration and Dosage Incretins Administration and Dosage Glucagon-Like Peptide-1 Receptor Agonists Adverse Effects Glucose Insulin Glucagon Appetite Gastrointestinal System Drug Effects Administration, Oral Injections, Subcutaneous ab: BACKGROUND: It is estimated that 29.1 million people or 9.3% of the US population have diabetes, which contributes to considerable medical and financial burden. Type 2 diabetes mellitus is characterized by insulin resistance and insulin secretion impairment leading to hyperglycemia. The presence of insulin resistance is strongly correlated with obesity. OBJECTIVE: This article reviews the available glucagon-like peptide-1 (GLP-1) receptor agonists and their role in the management of patients with diabetes, to help guide the selection of the most suitable agent for the individualized treatment of patients with type 2 diabetes. DISCUSSION: This article reviews the evidence from phase 3 clinical trials for each of the 5 GLP-1 receptor agonists by comparing them against one another and with other existing therapies, including metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sulfonylureas. Incretin-based therapies have emerged as attractive agents for the treatment of type 2 diabetes. They target the GLP-1 hormone, which is partly responsible for insulin release and for attenuating hyperglycemia during meals (ie, the incretin effect). The 2 classes of incretin-based therapy currently available are GLP-1 receptor agonists and DPP-4 inhibitors, which prevent the breakdown of GLP-1. Both classes are attractive options, given their glucose- lowering effects without the adverse effects of hypoglycemia and weight gain. The different mechanisms of action of these therapies result in generally greater efficacy with GLP-1 receptor agonists, albeit at the expense of slightly increased gastrointestinal symptoms. These agents exert their effects by improving glucose-dependent insulin release, suppressing glucagon release, suppressing hepatic glucose output, and decreasing the rate of gastric emptying, thereby reducing appetite. Currently, 5 GLP-1 receptor agonists are available, including exenatide, liraglutide, albiglutide, dulaglutide, and lixisenatide; semaglutide may soon become available as the newest agent. With the exception of the investigational oral semaglutide, which has shown promising results, the other 5 agents are administered as subcutaneous injections, at different dosing intervals. CONCLUSION: Currently, 5 GLP-1 receptor agonists are available for use in the United States. Although they are all in the same drug class, some significant differences exist among the various GLP-1 receptor agonists. The choice of a specific GLP-1 receptor agonist will depend on the patient preferences, potential adverse effects, and cost. pubtype: Periodical doctype: commentary research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|